Principles of dose finding studies in cancer: a comparison of trial designs Thomas JakiSally CliveChristopher J. Weir Review Article Open access 09 January 2013 Pages: 1107 - 1114
A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis Samira Sadat AbolmaaliAli Mohammad TamaddonRassoul Dinarvand Review Article 06 January 2013 Pages: 1115 - 1130
Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution Zhenzhen LiuYukun FengXiaohui Chen Original Article 15 February 2013 Pages: 1131 - 1139
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer Eiichiro SuzukiMasafumi IkedaJunji Furuse Original Article Open access 24 March 2013 Pages: 1141 - 1146
Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts Maurizio RocchettiMassimiliano GermaniGiuseppe De Nicolao Original Article 21 February 2013 Pages: 1147 - 1157
Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel Hao WuMin HuangPing Liu Original Article 20 February 2013 Pages: 1159 - 1171
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer N. RamnathS. Daignault-NewtonD. L. Trump Original Article 23 February 2013 Pages: 1173 - 1182
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer Rachel M. LaymanAmy S. RuppertCharles L. Shapiro Original Article 21 February 2013 Pages: 1183 - 1190
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation Ruth PlummerPaul LoriganHilary Calvert Original Article 20 February 2013 Pages: 1191 - 1199
Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Soo Jung LeeJong Gwang KimGyu Seog Choi Original Article 19 February 2013 Pages: 1201 - 1207
A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation Viswa Kalyan KolliIndirani KanakasabapathyPremila Abraham Original Article 19 February 2013 Pages: 1209 - 1218
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice Dipti K. PawaskarRobert M. StraubingerWilliam J. Jusko Original Article 03 March 2013 Pages: 1219 - 1229
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice Dipti K. PawaskarRobert M. StraubingerWilliam J. Jusko Original Article 03 March 2013 Pages: 1231 - 1240
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors Jennifer A. ChanRobert J. MayerMatthew H. Kulke Original Article 09 March 2013 Pages: 1241 - 1246
A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors J. CapdevilaS. CliveJ. Tabernero Original Article 02 March 2013 Pages: 1247 - 1254
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1 Jing-Ming ZhaiXiao-Yu YinLong-Juan Zhang Original Article 23 February 2013 Pages: 1255 - 1264
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis S. FushidaJ. KinoshitaSociety for the Study of Peritoneal Carcinomatosis in Gastric Cancer Original Article Open access 20 February 2013 Pages: 1265 - 1272
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies Laura Q. M. ChowDerek I. JonkerScott A. Laurie Original Article 07 March 2013 Pages: 1273 - 1285
Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer Wan ZhaoLingmin HuYongmei Yin Original Article 12 March 2013 Pages: 1287 - 1295
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib Maria SerovaArmand de GramontEric Raymond Original Article 12 March 2013 Pages: 1297 - 1307
Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer Akira TsuburayaNaoki NagataJunichi Sakamoto Original Article 05 March 2013 Pages: 1309 - 1314
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models Joseph M. GozgitRachel M. SquillaceVictor M. Rivera Original Article 07 March 2013 Pages: 1315 - 1323
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer Makoto SudoTan Min ChinH. Phillip Koeffler Original Article Open access 21 March 2013 Pages: 1325 - 1334
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro Juan Pablo RigalliTasmin ReuterDirk Theile Original Article 12 March 2013 Pages: 1335 - 1343
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors M. W. SaifC. ErlichmanD. Von Hoff Original Article 06 April 2013 Pages: 1345 - 1355
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias Robert O’ConnorMelissa G. OoiPeter O’Gorman Original Article 16 April 2013 Pages: 1357 - 1368
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer Mayu YunokawaNoriyuki KatsumataYasuhiro Fujiwara Original Article 05 April 2013 Pages: 1369 - 1374
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer John RinehartSusanne ArnoldMark Leggas Clinical Trial Report 09 March 2013 Pages: 1375 - 1383
Dodging a dogma: is treating beyond progression beneficial? Aung NaingRazelle Kurzrock Short Communication 27 February 2013 Pages: 1385 - 1386